GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » GlucoTrack Inc (NAS:GCTK) » Definitions » Altman Z-Score

GCTK (GlucoTrack) Altman Z-Score : N/A (As of Dec. 15, 2024)


View and export this data going back to 2000. Start your Free Trial

What is GlucoTrack Altman Z-Score?

The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.

GlucoTrack has a Altman Z-Score of N/A, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.

The zones of discrimination were as such:

When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.

The historical rank and industry rank for GlucoTrack's Altman Z-Score or its related term are showing as below:

During the past 13 years, GlucoTrack's highest Altman Z-Score was 22.18. The lowest was -202.63. And the median was -26.73.


GlucoTrack Altman Z-Score Historical Data

The historical data trend for GlucoTrack's Altman Z-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GlucoTrack Altman Z-Score Chart

GlucoTrack Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Altman Z-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -104.54 14.18 - - -

GlucoTrack Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Altman Z-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of GlucoTrack's Altman Z-Score

For the Medical Instruments & Supplies subindustry, GlucoTrack's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GlucoTrack's Altman Z-Score Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, GlucoTrack's Altman Z-Score distribution charts can be found below:

* The bar in red indicates where GlucoTrack's Altman Z-Score falls into.



GlucoTrack Altman Z-Score Calculation

Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

GlucoTrack's Altman Z-Score for today is calculated with this formula:

Z=1.2*X1+1.4*X2+3.3*X3+0.6*X4+1.0*X5
=1.2*-4.8051+1.4*-148.1308+3.3*-15.8196+0.6*0.7717+1.0*0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.

Trailing Twelve Months (TTM) ended in Sep. 2024:
Total Assets was $0.83 Mil.
Total Current Assets was $0.64 Mil.
Total Current Liabilities was $4.61 Mil.
Retained Earnings was $-122.36 Mil.
Pre-Tax Income was -5.087 + -4.489 + -2.927 + -2.412 = $-14.92 Mil.
Interest Expense was -1.848 + 0 + 0 + 0 = $-1.85 Mil.
Revenue was 0 + 0 + 0 + 0 = $0.00 Mil.
Market Cap (Today) was $3.74 Mil.
Total Liabilities was $4.85 Mil.

* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.

X1=Working Capital/Total Assets
=(Total Current Assets - Total Current Liabilities)/Total Assets
=(0.642 - 4.611)/0.826
=-4.8051

X2=Retained Earnings/Total Assets
=-122.356/0.826
=-148.1308

X3=Earnings Before Interest and Taxes/Total Assets
=(Pre-Tax Income - Interest Expense)/Total Assets
=(-14.915 - -1.848)/0.826
=-15.8196

X4=Market Value Equity/Book Value of Total Liabilities
=Market Cap/Total Liabilities
=3.741/4.848
=0.7717

X5=Revenue/Total Assets
=0/0.826
=0

The zones of discrimination were as such:

Distress Zones - 1.81 < Grey Zones < 2.99 - Safe Zones

GlucoTrack has a Altman Z-Score of N/A indicating it is in Distress Zones.

Study by Altman found that companies that are in Distress Zone have more than 80% of chances of bankruptcy in two years.


GlucoTrack  (NAS:GCTK) Altman Z-Score Explanation

X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.

X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.

X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.

X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.

X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.

Read more about Altman Z-Score and the original research.


Be Aware

Altman Z-Score does not apply to financial companies.


GlucoTrack Altman Z-Score Related Terms

Thank you for viewing the detailed overview of GlucoTrack's Altman Z-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


GlucoTrack Business Description

Traded in Other Exchanges
N/A
Address
301 Route 17 North, Suite 800, Rutherford, New Jersey, NJ, USA, 07070
GlucoTrack Inc is a medical device company. It focuses on the design, development, and commercialization of non-invasive glucose monitoring devices for use by people with diabetes and pre-diabetics. The company has developed a non-invasive glucose monitor, the GlucoTrack model DF-F glucose monitoring device, which is designed to help people with diabetes and pre-diabetics obtain glucose level readings without the pain, inconvenience, and difficulty of conventional spot finger stick devices. It has completed a feasibility study successfully demonstrating that a minimum two-year implant life is highly probable with the sensor design. They have also initiated an animal study with an initial prototype system that has thus far demonstrated a simple implant procedure and good functionality.
Executives
Drew Sycoff director C/O ANDREW GARRETT INC, 52 VANDERBILT AVENUE - 20TH FLOOR, NEW YORK NY 10017
James S Cardwell officer: Chief Financial Officer CLINTON SQUARE, 75 S. CLINTON AVE., SUITE 510, ROCHESTER NY 14604
Erin Catherine Carter director 301 RTE 17 NORTH, STE. 800, RUTHERFORD NJ 07070
Allen Danzig director 301 RT 17 NORTH, SUITE 800, RUTHERFORD NJ 07070
Shimon D Rapps director C/O ANDREW GARRETT, INC., 52 VANDERBILT AVENUE SUITE 510, NEW YORK NY 10017
David Podwalski officer: Chief Commercial Officer 19 HA'YAHALOMIM ST., P.O. BOX 12163, ASHDOD L3 7760049
Michael Hauck director 19 HA'YAHALOMIM ST., P.O. BOX 12163, C/O INTEGRITY APPLICATIONS, INC., ASHDOD L3 7760049
John A Graham director, officer: Chief Executive Officer 19 HA'YAHALOMIM STREET, P.O. BOX 12163, ASHDOD L3 7760049
Sami Sassoun officer: Chief Financial Officer 39-06 ACKERMAN DRIVE, FAIR LAWN L3 7760049
Philip Darivoff director 1 FARMSTEAD ROAD, SHORT HILLS NJ 07078
Revan Schwartz director 19 HA'YAHALOMIM ST., P.O. BOX 12163, C/O INTEGRITY APPLICATIONS, INC., ASHDOD L3 7760049
Leslie Seff director PO BOX 59, 40 HELLBROOK LANE, ULSTER PARK NY 12487
Angela Strand Boydston director C/O AEROGEN, INC., 2071 STIERLIN COURT, MOUNTAIN VIEW CA 94043
Eran Hertz officer: Chief Financial Officer C/O INTEGRITY APPLICATIONS, INC., 102 HA'AVODA STREET, P.O. BOX 432, ASHKELON L3 L3 78100
Israel B. Ehrlich director C/O INTEGRITY APPLICATIONS, INC., 102 HA'AVODA STREET, P.O. BOX 432, ASHKELON L3 L378100